Lecanemab Receives Priority Review Status in Japan
TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read Moreป้ายกำกับ: submitted
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read More
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read More